WO2005105139A2 - Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy - Google Patents
Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy Download PDFInfo
- Publication number
- WO2005105139A2 WO2005105139A2 PCT/EP2005/004956 EP2005004956W WO2005105139A2 WO 2005105139 A2 WO2005105139 A2 WO 2005105139A2 EP 2005004956 W EP2005004956 W EP 2005004956W WO 2005105139 A2 WO2005105139 A2 WO 2005105139A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oil
- vaccine
- antigen
- present
- adjuvant
- Prior art date
Links
- 238000002619 cancer immunotherapy Methods 0.000 title 1
- 229940031348 multivalent vaccine Drugs 0.000 title 1
- 239000002671 adjuvant Substances 0.000 claims abstract description 53
- 229960005486 vaccine Drugs 0.000 claims abstract description 49
- 239000000427 antigen Substances 0.000 claims abstract description 35
- 102000036639 antigens Human genes 0.000 claims abstract description 35
- 108091007433 antigens Proteins 0.000 claims abstract description 35
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 30
- 230000003308 immunostimulating effect Effects 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 229930182490 saponin Natural products 0.000 claims abstract description 20
- 150000007949 saponins Chemical class 0.000 claims abstract description 20
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 15
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims abstract description 13
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims abstract description 13
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 claims abstract description 6
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 claims abstract description 6
- 239000000839 emulsion Substances 0.000 claims description 32
- 239000002158 endotoxin Substances 0.000 claims description 19
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 18
- 239000007764 o/w emulsion Substances 0.000 claims description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 16
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 16
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 15
- 239000002502 liposome Substances 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 235000012000 cholesterol Nutrition 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- 229940037003 alum Drugs 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 229930003799 tocopherol Natural products 0.000 claims description 4
- 239000011732 tocopherol Substances 0.000 claims description 4
- 235000010384 tocopherol Nutrition 0.000 claims description 4
- 229960001295 tocopherol Drugs 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 abstract description 17
- 201000011510 cancer Diseases 0.000 abstract description 10
- 238000009472 formulation Methods 0.000 abstract description 8
- 239000003921 oil Substances 0.000 description 39
- 235000019198 oils Nutrition 0.000 description 39
- 108090000623 proteins and genes Proteins 0.000 description 18
- 235000017709 saponins Nutrition 0.000 description 16
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 9
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 9
- 230000009885 systemic effect Effects 0.000 description 9
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 229940031439 squalene Drugs 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 6
- 229940087168 alpha tocopherol Drugs 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 229960000984 tocofersolan Drugs 0.000 description 6
- 239000002076 α-tocopherol Substances 0.000 description 6
- 235000004835 α-tocopherol Nutrition 0.000 description 6
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 5
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 4
- -1 PAGE family Proteins 0.000 description 4
- 101710188053 Protein D Proteins 0.000 description 4
- 101710132893 Resolvase Proteins 0.000 description 4
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000012646 vaccine adjuvant Substances 0.000 description 4
- 229940124931 vaccine adjuvant Drugs 0.000 description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical group [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
- 108700023418 Amidases Proteins 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 102100029894 Bromodomain testis-specific protein Human genes 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 102100039361 Chondrosarcoma-associated gene 2/3 protein Human genes 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 241000305071 Enterobacterales Species 0.000 description 2
- 101000794028 Homo sapiens Bromodomain testis-specific protein Proteins 0.000 description 2
- 101000745414 Homo sapiens Chondrosarcoma-associated gene 2/3 protein Proteins 0.000 description 2
- 108091081548 Palindromic sequence Proteins 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 102000005922 amidase Human genes 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 150000002016 disaccharides Chemical group 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 0 C*(C)(C([N+]C)O*)C#N Chemical compound C*(C)(C([N+]C)O*)C#N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000040452 GAGE family Human genes 0.000 description 1
- 108091072337 GAGE family Proteins 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101001054842 Homo sapiens Leucine zipper protein 4 Proteins 0.000 description 1
- 101000938702 Homo sapiens N-acetyltransferase ESCO1 Proteins 0.000 description 1
- 101000633613 Homo sapiens Probable threonine protease PRSS50 Proteins 0.000 description 1
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100026910 Leucine zipper protein 4 Human genes 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 101100499365 Mus musculus Dlk1 gene Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- KTHDTJVBEPMMGL-VKHMYHEASA-N N-acetyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(C)=O KTHDTJVBEPMMGL-VKHMYHEASA-N 0.000 description 1
- KTHDTJVBEPMMGL-UHFFFAOYSA-N N-acetyl-L-alanine Natural products OC(=O)C(C)NC(C)=O KTHDTJVBEPMMGL-UHFFFAOYSA-N 0.000 description 1
- 241001644525 Nastus productus Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229910018828 PO3H2 Inorganic materials 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000036673 PRAME Human genes 0.000 description 1
- 108060006580 PRAME Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 102100029523 Probable threonine protease PRSS50 Human genes 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 101710132582 Protein D1 Proteins 0.000 description 1
- 102100037686 Protein SSX2 Human genes 0.000 description 1
- 241001454523 Quillaja saponaria Species 0.000 description 1
- 235000009001 Quillaja saponaria Nutrition 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 102000042330 SSX family Human genes 0.000 description 1
- 108091077753 SSX family Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000607149 Salmonella sp. Species 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 description 1
- 101710185775 Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102400000368 Surface protein Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100027244 U4/U6.U5 tri-snRNP-associated protein 1 Human genes 0.000 description 1
- 101710155955 U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 230000001448 gametogenic effect Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 101150082581 lytA gene Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000002126 nonhaemolytic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000601 reactogenic effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 239000010686 shark liver oil Substances 0.000 description 1
- 229940069764 shark liver oil Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940093609 tricaprylin Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 229940023147 viral vector vaccine Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
Definitions
- Vaccines The present invention relates to a novel vaccine formulation comprising (a) an antigen component comprising a combination of a modified MAGE-3 antigen and an NY-ESO-1 antigen, or derivatives thereof, and (b) an adjuvant.
- an antigen component comprising a combination of a modified MAGE-3 antigen and an NY-ESO-1 antigen, or derivatives thereof
- an adjuvant comprising an adjuvant.
- CT cancer/testis
- MAGE-3 and NY-ESO-1 are known as the prototype CT antigens.
- the family of CT antigens also includes members of the NY-ESO-1, PRAME, GAGE family, PAGE family, BAGE, XAGE family, LAGE, members of the SSX family ( amongst which SSX- 1 , -2 also known as HOM-MEL-40, -4, -5), SCP- 1 (aslo l ⁇ iown as HOM- TES-14), SART-1 and SART-3, HOM-TES-85, sperm-protein Spl7, CTpll, TSP50, CT9/BRDT, TRAG-3 (Taxol Resistance Associated Gene-3), OY-MS-4MAGE (see Table 1 in Kirkin A. et al. Cancer Investigation, 2002, 20(2), 222-236).
- the present invention relates to novel vaccine formulations comprising: (a) an antigen component comprising combination of a modified MAGE-3 antigen and an NY-ESO-1 antigen or derivative thereof, and (b) an immunostimulatory adjuvant comprising one or more of: alum salt; cholesterol; oil-in-water emulsion (O/W emulsion); oil-in-water emulsion low dose; an immunostimulatory oligonucleotide; tocopherol; liposome; a saponin; and a lipopolysaccharide .
- an antigen component comprising combination of a modified MAGE-3 antigen and an NY-ESO-1 antigen or derivative thereof
- an immunostimulatory adjuvant comprising one or more of: alum salt; cholesterol; oil-in-water emulsion (O/W emulsion); oil-in-water emulsion low dose; an immunostimulatory oligonucleotide; tocopherol; liposome; a sapon
- a vaccine composition comprising (a) an antigen component comprising a fusion protein of MAGE 3 and a truncated Protein D carrier protein (MAGE3-ProteinD 1/3) of SEQ ID NO:l (as described both herein and as described in WO 99/40188), an NY-ESO-1 protein antigen, and (b) an adjuvant composition comprising liposome structures containing cholesterol and QS21, in combination with an immunostimulatory oligonucleotide which contains at least one unmethylated oligonucleotide.
- MAGE3-ProteinD 1/3 truncated Protein D carrier protein
- an adjuvant composition comprising liposome structures containing cholesterol and QS21, in combination with an immunostimulatory oligonucleotide which contains at least one unmethylated oligonucleotide.
- the vaccines of the present invention may improve the antitumour effect of the cancer vaccines in comparison with a vaccine containing only one of the antigens expressed by a tumour cell. This improved vaccine would not necessarily enable greater patient coverage (ie., allow more cancers to be targeted with one vaccine), but also allow a better immune response to be generated against the targeted tumour.
- the vaccines of the present invention may reduce the chance of tumour evasion or escape, even if expression of one of the antigens is reduced after vaccination.
- the invention relates to the specific combination of the following components: (i) modified MAGE protein (MAGE3-ProteinD 1/3), as shown in SEQ TD NO:l (ii) an "immunogenic region" of NY-ESOl gene product, for example: the NY- ESO1 protein; a protein, polypeptide or peptide consisting of or comprising the C terminal portion of the protein containing the Class I and/or Class II epitopes of NY-ESOl; overlapping longpeptides comprising this region; and/or, specific CD8 peptides.
- an immunostimulatory adjuvant comprising one or more of: alum salt; cholesterol; oil-in-water emulsion (O/W emulsion); oil-in-water emulsion low dose; an immunostimulatory oligonucleotide, for example CpG; tocopherol; liposome; a saponin, for example QS21; and a lipopolysaccharide, for example MPL.
- adjuvants suitable for use in the present invention include those comprising or consisting of the following components: a. CpG; O/W emulsion/3D-MPL/QS21 (high dose); b.
- the adjuvant is: CpG/MPL/QS21/liposomes
- Components (i) and (ii) may be co-formulated with component (iii) for concomitant administration, or may each be separately formulated with component (iii) for concomitant or sequential administration.
- component (i) is formulated with an adjuvant component (iii) which comprises CpG/MPL/QS21/liposomes and component (ii) is formulated with an adjuvant component (iii) which comprises ISCOMS, for example QS21- containing ISCOMS or ISCOMS comprising QS21 and QS7.
- component (i) and (ii) are provided for concomitant or sequential administration.
- Components (i) and (ii) may be expressed as separate components, or may be expressed as a fusion protein.
- a DNA/viral vector vaccine is also envisaged, in which the vaccine comprises nucleic acid encoding components (i) and (ii), and component (iii) is a suitable adjuvant for a DNA vaccine.
- the vaccine compositions comprise a MAGE-3 derivative antigen.
- the derivative is a fusion protein comprising a MAGE-3 antigen linked to a heterologous partner.
- the proteins may be chemically conjugated, or may be expressed as recombinant fusion proteins thus allowing increased levels to be produced in an expression system as compared to non-fused protein.
- the fusion partner may assist in providing T helper epitopes (immunological fusion partner), for example T helper epitopes recognised by humans, or assist in expressing the protein (expression enhancer) at higher yields than the native recombinant protein.
- the fusion partner will be both an immunological fusion partner and expression enhancing partner.
- the MAGE-3 immunological fusion partner is derived from protein D, a surface protein of the gram-negative bacterium, Haemophilus influenza B (WO91/18926).
- the protein D derivative comprises approximately the first 1/3 of the protein, in particular approximately the first N-terminal 100-110 amino acids.
- the protein D derivative is lipidated.
- the first 109 residues of the Lipoprotein D fusion partner is included on the N-terminus to provide the vaccine candidate antigen with additional exogenous T-cell epitopes and increase expression level in E-coli (thus acting also as an expression enhancer). The lipid tail ensures optimal presentation of the antigen to antigen presenting cells.
- MAGE-3 fusion partners include the non-structural protein from influenzae virus, NS1 (hemagglutinin). Typically the N terminal 81 amino acids are utilised, although different fragments may be used provided they include T-helper epitopes.
- the MAGE-3 immunological fusion partner is the protein known as LYTA.
- the C terminal portion of the molecule is used. Lyta is derived from Streptococcus pneumoniae which synthesize an N- acetyl-L-alanine amidase, amidase LYTA, (coded by the lytA gene ⁇ Gene, 43 (1986) page 265-272 ⁇ an autolysin that specifically degrades certain bonds in the peptidoglycan backbone.
- the C-tenninal domain of the LYTA protein is responsible for the affinity to the choline or to some chorine analogues such as DEAE. This property has been exploited for the development of E.coli C-LYTA expressing plasmids useful for expression of fusion proteins. Purification of hybrid proteins containing the C-LYTA fragment at its amino terminus has been described ⁇ Biotechnology: 10, (1992) page 795-798 ⁇ . As used herein, one embodiment of the invention utilises the repeat portion of the Lyta molecule found in the C terminal end starting at residue 178. One form which may be used incorporates residues 188 - 305.
- the modified MAGE-3 composition comprises an antigen as disclosed in WO 99/40188, or immunogenic fragment such as a peptide having retained the capability of eliciting an immune response which recognises the MAGE protein.
- a specific antigen for the present vaccines is the MAGE-3 polypeptide having the amino acid sequence set forth in Gaugler B. et al., J. Exp. Med., 1994, 179, 921 (MAGE-3), or in SEQ TD NO:l (protein D1/3-MAGE-3) (both herein and also in WO 99/40188) .
- Said immunogenic composition can be prepared according to the method disclosed in WO 99/40188 or by any routine technique known to the skilled in the art.
- NY-ESO-1 is a tumour associated antigen described in WO 98/14464, the contents of which are incorporated in full into this disclosure. NY-ESO-1 is also described in Chen YT et al, Proc NatlAcad Sci USA 1997, 94: 1914-18; Scanlan et al., 2004, Cancer Immunity, 4, 1. The protein and polynucleotide sequence for NY- ESO-1 is provided in Genbank ACCESSION No. U87459, Version U87459.1 (SEQ LO Nos 2 and 3).
- the vaccine adjuvant that forms part of the present invention comprises an immunostimulatory adjuvant comprising one or more of: alum salt; cholesterol; oil-in-water emulsion (O/W emulsion); oil-in-water emulsion low dose; an immunostimulatory oligonucleotide; tocopherol; liposome; a saponin; and a lipopolysaccharide.
- the adjuvant comprises an immunostimulatory oligonucleotide, a saponin, and optionally a derivative of Lipopolysaccharide (LPS).
- the vaccine of the present invention may further comprise a carrier.
- CpG Immunostimulatory oligonucleotides containing unmethylated CpG dinucleotides
- CpG is an abbreviation for cytosine-guanosine dinucleotide motifs present in DNA. Historically, it was observed that the DNA fraction of BCG could exert an anti-tumour effect.
- the immunostimulatory sequence is often: Purine, Purine, C, G, pyrimidine, pyrimidine; wherein the dinucleotide CG motif is not methylated, but other unmethylated CpG sequences are known to be immunostimulatory and may be used in the present invention.
- a palindromic sequence is present.
- Several of these motifs, either as repeats of one motif or a combination of different motifs, can be present in the same oligonucleotide.
- CpG when formulated into vaccines, is generally administered in free solution together with free antigen (WO 96/02555; McCluskie and Davis, supra) or covalently conjugated to an antigen (PCT Publication o. WO 98/16247), or formulated with a carrier such as aluminium hydroxide ((Hepatitis surface antigen) Davis et al.
- the oligonucleotides for use in the vaccines of the present invention may contain at least one unmethylated CpG motifs separated by at least three, or at least six or more nucleotides.
- the oligonucleotides of the present invention are typically deoxynucleotides.
- the internucleotide in the oligonucleotide is phosphorodithioate. In another embodiment,the internucleotide is a phosphorothioate bond.
- phosphodiester and other internucleotide bonds are within the scope of the invention including oligonucleotides with mixed internucleotide linkages.
- Methods for producing phosphorothioate oligonucleotides or phosphorodithioate are described in US5,666,153, US5,278,302 and WO95/26204.
- Examples of oligonucleotides which may be used have the following sequences. The sequences may contain phosphorothioate modified internucleotide linkages.
- OLIGO 1(SEQ LO NO:4) TCC ATG ACG TTC CTG ACG TT (CpG 1826)
- OLIGO 2 SEQ ID NO:5): TCT CCC AGC GTG CGC CAT (CpG 1758)
- OLIGO 3 SEQ LO NO:6): ACC GAT GAC GTC GCC GGT GAC GGC ACC ACG
- OLIGO 4 SEQ TD NO:7): TCG TCG TTT TGT CGT TTT GTC GTT (CpG 2006)
- OLIGO 5 SEQ TD NO: 8: TCC ATG ACG TTC CTG ATG CT (CpG 1668)
- Alternative CpG oligonucleotides may comprise the sequences above in that they have inconsequential deletions or additions thereto.
- the CpG oligonucleotides utilised in the present invention may be synthesized by any method known in the art (eg EP 468520). Conveniently, such oligonucleotides may be synthesized utilising an automated synthesizer. They are typically between 10-50 bases in length.
- the oligonucleotides utilised in the present invention are typically deoxynucleotides.
- the internucleotide bond in the oligonucleotide is phosphorodithioate, or more for example phosphorothioate bond, although phosphodiesters are within the scope of the present invention.
- Oligonucleotide comprising different internucleotide linkages are contemplated, e.g. mixed phosphorothioate phophodiesters.
- Other internucleotide bonds which stabilise the oligonucleotide may be used.
- the saponins which may be used in the vaccine combinations of the present invention include those derived from the bark of Quillaja Saponaria Molina, termed Quil A, and fractions thereof, described in US 5,057,540 and "Saponins as vaccine adjuvants", Kensil, C. R., Crit Rev Ther Drug Carrier Syst, 1996, 12 (1-2):1- 55; and EP 0 362 279 Bl.
- suitable fractions of Quil A are QS21, QS7, and QS 17.
- the haemolytic saponins QS21 and QS 17 HPLC purified fractions of Quil A have been described as potent systemic adjuvants, and the method of their production is disclosed in U.S. Pat.
- the adjuvant component comprises a QS21-containing ISCOM.
- the adjuvant component comprises ISCOMS comprising QS21 and QS7.
- the adjuvant combinations of the present invention may further comprise a carrier, the carrier may be simply admixed with the adjuvants or alternatively the adjuvants may be associated with a particulate carrier entity to enhance the adjuvanticity of the combination.
- Systemic vaccines may, for example, comprise a carrier molecule.
- Exemplary carriers include mineral salts (for example, but not restricted to, aluminium or calcium salts), liposomes, ISCOMs, emulsions (oil in water, water in oil, water in oil in water), polymers (such as, but not restricted to polylactic, polyglycolic, polyphosphazine, polyaminoacid, alginate, chitosan) or microparticles.
- the vaccines of the present invention further comprise an antigen which may be associated with the CpG-carrier complex, or may not be associated with the CpG-carrier complex.
- the antigen may be free suspension or associated with a separate carrier.
- the saponins forming part of the present invention may be separate in the form of micelles, or may be in the form of large ordered structures such as ISCOMs (EP 0 109 942 Bl) or liposomes when formulated with cholesterol and lipid ("DQ" described in WO 96/33739), or in the form of an oil in water emulsion (WO 95/17210).
- the saponins maybe associated with a metallic salt, such as aluminium hydroxide or aluminium phosphate (WO 98/15287).
- the saponin may be associated with a particulate carrier such as chitosan.
- the saponin may also be in a dry state such as a powder.
- the final formulations in the form as they are administered to the mucosal surface of the vaccinee may be haemolytic in nature.
- the saponin may or may not be associated physically with the antigen either through direct linkage or by co-interaction with the same particulate carrier molecule (GB9822712.7; WO 98/16247).
- the CpG and saponin which may be used in the adjuvants or vaccines of the present invention may themselves be separate or associated.
- the CpG and saponin may be in free suspension or may be associated via a carrier, for example a particulate carrier such as aluminium hydroxide or by a cationic liposome or ISCOM.
- a carrier for example a particulate carrier such as aluminium hydroxide or by a cationic liposome or ISCOM.
- An example of an adjuvant combination according to the present invention is composed of one or more CpG oligonucleotides containing at least 3, or at least 6 nucleotides between two adjacent CG motifs, together with QS21 and a particulate carrier selected from the group comprising an oil-in-water emulsion or DQ.
- the lipopolysacchhari.de may be a di or monophosphoryl lipid derivative.
- the lipopolysaccharide may be 3 de-O acylated, in particular 3 de O acylated monophosphoryl Lipid A.
- the adjuvant combination comprises CpG 2006 (SEQ ID NO: 4), or CpG 1758 (SEQ ID NO: 2) or CpG 1826 (SEQ ID NO: 1) mixed with QS21, and a particulate carrier selected from the group comprising an oil-in-water emulsion or DQ.
- vaccines of the invention may, for example, comprise such adjuvant combinations and an antigen.
- the vaccine of the present invention may be used to generate systemic immune responses after administration to an individual through the systemic route.
- adjuvant compositions that may form part of vaccines of the present invention are described in WO00/62800.
- the adjuvant combinations of the present invention can comprise an oil based emulsion.
- Oil emulsion adjuvants have been known for many years, including work on Freunds complete and incomplete mineral oil emulsion adjuvants. Since that time much work has been performed to design stable and well tolerated alternatives to these potent, but reactogenic, adjuvant formulations. Many single or multiphase emulsion systems have been described.
- Oil in water emulsion adjuvants per se have been suggested to be useful as adjuvant compositions (EP O 399 843B), also combinations of oil in water emulsions and other active agents have been described as adjuvants for vaccines (WO 95/17210; WO 98/56414; WO 99/12565; WO 99/11241).
- Other oil emulsion adjuvants have been described, such as water in oil emulsions (US 5,422,109; EP 0 480 982 B2) and water in oil in water emulsions (US 5,424,067; EP 0 480 981 B).
- the oil emulsion adjuvants for use in the present invention may be natural or synthetic, and may be mineral or organic.
- the oil phase of the emulsion system may comprise a metabolisable oil.
- metabolisable oil is well known in the art. Metabolisable can be defined as "being capable of being transformed by metabolism” (Dorland's Illustrated Medical Dictionary, W.B. Sanders Company, 25th edition (1974)).
- the oil may be any vegetable oil, fish oil, animal oil or synthetic oil, which is not toxic to the recipient and is capable of being transformed by metabolism. Nuts (such as peanut oil), seeds, and grains are common sources of vegetable oils. Synthetic oils are also part of this invention and can include commercially available oils such as NEOBEE® and others.
- Squalene (2,6,10,15,19,23-Hexamethyl-2,6,10,14,18,22-tetracosahexaene) is an unsaturated oil which is found in large quantities in shark-liver oil, and in lower quantities in olive oil, wheat germ oil, rice bran oil, and yeast, and is an oil suitable for use in this invention.
- Squalene is a metabolisable oil virtue of the fact that it is an intermediate in the biosynthesis of cholesterol (Merck index, 10th Edition, entry no.8619).
- Examples of oil emulsions for use in the present invention are oil in water emulsions, and in particular squalene in water emulsions.
- oil emulsion adjuvants of the present invention may comprise an antioxidant, which may be the oil ⁇ -tocopherol (vitamin E, EP 0 382 271 Bl).
- an antioxidant which may be the oil ⁇ -tocopherol (vitamin E, EP 0 382 271 Bl).
- WO 95/17210 and WO 99/11241 disclose emulsion adjuvants based on squalene, ⁇ -tocopherol, and TWEEN 80, optionally formulated with the immunostimulants QS21 and/or 3D-MPL.
- WO 99/12565 discloses an improvement to these squalene emulsions with the addition of a sterol into the oil phase.
- a triglyceride such as tricaprylin (C27H50O6), may be added to the oil phase in order to stabilise the emulsion (WO 98/56414).
- the size of the oil droplets found within the stable oil in water emulsion may be less than 1 micron, may be in the range of substantially 30-600nm, for example substantially around 30-500nm in diameter, and for example substantially 150-500nm in diameter, and in particular about 150 nm in diameter as measured by photon correlation spectroscopy.
- 80% of the oil droplets by number should be within these exemplified ranges, or for example more than 90% or more than 95% of the oil droplets by number should be within the defined size ranges.
- the amounts of the components present in the oil emulsions of the present invention are conventionally in the range of from 2 to 10% oil, such as squalene; and when present, from 2 to 10% alpha tocopherol; and from 0.3 to 3% surfactant, such as polyoxyethylene sorbitan monooleate.
- the ratio of oil: alpha tocopherol may be equal or less than 1 as this provides a more stable emulsion.
- Span 85 may also be present at a level of about 1%.
- the vaccines of the present invention will further contain a stabiliser.
- the method of producing oil in water emulsions is well known to the man skilled in the art.
- the method comprises the mixing the oil phase with a surfactant such as a PBS/TWEEN80TM solution, followed by homogenisation using a homogenizer, it would be clear to a man skilled in the art that a method comprising passing the mixture twice through a syringe needle would be suitable for homogenising small volumes of liquid.
- a surfactant such as a PBS/TWEEN80TM solution
- a homogenizer it would be clear to a man skilled in the art that a method comprising passing the mixture twice through a syringe needle would be suitable for homogenising small volumes of liquid.
- the emulsification process in microfluidiser MHOS microfluidics machine, maximum of 50 passes, for a period of 2 minutes at maximum pressure imput of 6 bar (output pressure of about 850 bar)
- MHOS microfluidics machine maximum of 50 passes, for a period of 2 minutes at maximum pressure imput of 6 bar (output pressure of about 850 bar)
- the vaccines of the present invention may be administered through the systemic or parenteral route such as intramuscular, intradermal, transdermal, subcutaneous, intraperitoneal or intravenous administration.
- the systemic vaccine preparations of the present invention may be used to protect or treat a mammal susceptible to, or suffering from cancer, by means of administering said vaccine by intramuscular, intraperitoneal, intradermal, transdermal, intravenous, or subcutaneous administration.
- the vaccines of the present invention may be used to treat individuals suffering from non-small cell lung carcinoma (NSCLC), Melanoma, or Bladder cancer.
- NSCLC non-small cell lung carcinoma
- Melanoma or Bladder cancer.
- a method for inducing an immune response against MAGE-3 and NY-ESO-1 in an individual comprising the administration of a vaccine according to the present invention to the individual.
- the amount of saponin for use in the adjuvants of the present invention may be in the region of l-1000 ⁇ g per dose, for example l-500 ⁇ g per dose, or for example l-250 ⁇ g per dose, or for example between 1 to lOO ⁇ g per dose.
- CpG: saponin (w/w) will, therefore, be in the range of 1 : 1000 to 1000 : 1 , and will typically be in the range of 1 : 100 to 100 : 1 , or for example in the range of 1 : 10 to 1 : 1 or 1:1 to 10:1. In one embodiment, the ratio is 1:1, 4:1 or 10:1.
- the amount of CpG or immunostimulatory oligonucleotides in the adjuvants or vaccines of the present invention is generally small, but depending on the vaccine formulation may be in the region of l-1000 ⁇ g per dose, for example l-500 ⁇ g per dose, or for example between 1 to lOO ⁇ g per dose.
- Vaccine preparation is generally described in New Trends and Developments in Vaccines, edited by Voller et al., University Park Press, Baltimore, Maryland, U.S.A. 1978.
- the invention therefore provides a method to prevent an individual from contracting a disease selected from the group comprising NSCLC, melanoma and bladder cancers; comprising the administration of a composition as substantially described herein through the systemic route of said individual.
- suitable pharmaceutically acceptable excipients for use in the combinations of the present invention include water, phosphate buffered saline, isotonic buffer solutions.
- the vaccine adjuvant component may further comprise a derivative of LPS, such as 3D-MPL.
- adjuvants examples include: combinations of CpG, 3D-MPL and QS21 (EP 0 671 948 Bl), oil in water emulsions comprising CpG, 3D- MPL and QS21 (WO 95/17210, WO 98/56414), or 3D-MPL formulated with other carriers (EP 0 689 454 Bl) in combination with the CpG oligonucleotides as herein described.
- the adjuvant combinations of the present invention may include at least one enterobacterial lipopolysaccharide derived adjuvant.
- enterobacterial lipopolysaccharide is a potent stimulator of the immune system, although its use in adjuvants has been curtailed by its toxic effects.
- LPS enterobacterial lipopolysaccharide
- MPL monophosphoryl lipid A
- a further detoxified version of MPL results from the removal of the acyl chain from the 3-position of the disaccharide backbone, and is called 3-O-Deacylated monophosphoryl lipid A (3D-MPL). It can be purified and prepared by the methods taught in GB 2122204B, which reference also discloses the preparation of diphosphoryl lipid A, and 3-O-deacylated variants thereof.
- 3D-MPL is in the form of an emulsion having a small particle size less than 0.2 ⁇ m in diameter, and its method of manufacture is disclosed in WO 94/21292.
- Aqueous formulations comprising monophosphoryl lipid A and a surfactant have been described in WO 98/43670A2.
- the bacterial lipopolysaccharide derived adjuvants which may be formulated in the adjuvant combinations of the present invention may be purified and processed from bacterial sources, or alternatively they may be synthetic.
- purified monophosphoryl lipid A is described in Ribi et al 1986 (supra)
- 3-O-Deacylated monophosphoryl or diphosphoryl lipid A derived from Salmonella sp. is described in GB 2220211 and US 4912094.
- Other purified and synthetic lipopolysaccharides have been described (WO 98/01139; US 6,005,099 and EP 0 729 473 Bl; Hilgers et al, 1986, Int.Arch.Allergy.
- LPS derivatives that may be used in the present invention are those immunostimulants that are similar in structure to that of LPS or MPL or 3D- MPL.
- LPS derivatives may be an acylated monosaccharide, which is a sub-portion to the above structure of MPL.
- An example of a disaccharide adjuvant is a purified or synthetic lipid A of the following formula:
- R2 may be H or PO3H2;
- R3 may be an acyl chain or ⁇ -hydroxymyristoyl or a 3-acyloxyacyl residue having the formula: o wherein R* « — C M— (CH ⁇ )jr— CHj, and wherein X and Y have a value of from 0 up to about 20.
- One exemplary vaccine formulation comprises a 0.5 ml adjuvant composition comprising an oil in water emulsion comprising and oil phase: about 12 mg alpha tocopherol, about 11 mg squalene, and about 5mg tween 80; and in the aqueous phase: 50 ⁇ g 3D-MPL and 50 ⁇ g QS21 and 500 ⁇ g CpG.
- Another exemplary vaccine formulation comprises an oil in water emulsion comprising and oil phase: about 2 mg alpha tocopherol, about 2mg squalene, and about lmg tween 80; and in the aqueous phase: 50 ⁇ g 3D-MPL and 50 ⁇ g QS21.
- a vaccine composition comprising modified MAGE protein, as described in WO9940188; an "immunogenic region" of NY-ESOl gene product, for example: the NY-ESOl protein; a protein, polypeptide or peptide consisting of or comprising the C terminal portion of the protein containing the Class I and/or Class II epitopes of NY-ESOl; overlapping long peptides comprising this region; and/or, specific CD8 peptides; an immunostimulatory adjuvant comprising one or more of an alum salt, an oil-in-water emulsion (O/W emulsion).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0510570-6A BRPI0510570A (en) | 2004-05-04 | 2005-05-02 | vaccine composition |
NZ550967A NZ550967A (en) | 2004-05-04 | 2005-05-02 | MAGE-3 and NY-ESO-1 based polyvalent vaccine for cancer immunotherapy |
MXPA06012723A MXPA06012723A (en) | 2004-05-04 | 2005-05-02 | Vaccines. |
EP05741937A EP1755657A2 (en) | 2004-05-04 | 2005-05-02 | Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy |
CA002564470A CA2564470A1 (en) | 2004-05-04 | 2005-05-02 | Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy |
AU2005237256A AU2005237256A1 (en) | 2004-05-04 | 2005-05-02 | MAGE-3 and NY-ESO-1 based polyvalent vaccine for cancer immunotherapy |
JP2007512044A JP2007536326A (en) | 2004-05-04 | 2005-05-02 | Multivalent vaccine for cancer immunotherapy based on MAGE-3 and NY-ESO-1 |
US11/568,566 US20070243196A1 (en) | 2004-05-04 | 2005-05-02 | Mage-3 and NY-ESO-1 Based Polyvalent Vaccine for Cancer Immunotherapy |
IL178681A IL178681A0 (en) | 2004-05-04 | 2006-10-17 | Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy |
NO20065480A NO20065480L (en) | 2004-05-04 | 2006-11-28 | Vaccines. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0409940.4 | 2004-05-04 | ||
GBGB0409940.4A GB0409940D0 (en) | 2004-05-04 | 2004-05-04 | Vaccine |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005105139A2 true WO2005105139A2 (en) | 2005-11-10 |
WO2005105139A3 WO2005105139A3 (en) | 2006-04-13 |
Family
ID=32482653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/004956 WO2005105139A2 (en) | 2004-05-04 | 2005-05-02 | Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy |
Country Status (16)
Country | Link |
---|---|
US (1) | US20070243196A1 (en) |
EP (1) | EP1755657A2 (en) |
JP (1) | JP2007536326A (en) |
CN (1) | CN1980691A (en) |
AU (1) | AU2005237256A1 (en) |
BR (1) | BRPI0510570A (en) |
CA (1) | CA2564470A1 (en) |
GB (1) | GB0409940D0 (en) |
IL (1) | IL178681A0 (en) |
MA (1) | MA28639B1 (en) |
MX (1) | MXPA06012723A (en) |
NO (1) | NO20065480L (en) |
NZ (1) | NZ550967A (en) |
RU (1) | RU2006138283A (en) |
WO (1) | WO2005105139A2 (en) |
ZA (1) | ZA200608693B (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007137986A2 (en) * | 2006-05-26 | 2007-12-06 | Glaxosmithkline Biologicals Sa | Vaccination against cancer |
WO2007147876A3 (en) * | 2006-06-21 | 2008-05-15 | Glaxosmithkline Biolog Sa | Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage- a3 -marker |
WO2008110372A1 (en) | 2007-03-13 | 2008-09-18 | University Of Zurich | Monoclonal human tumor-specific antibody |
WO2008142133A1 (en) * | 2007-05-24 | 2008-11-27 | Glaxosmithkline Biologicals S.A | Lyophilised antigen composition |
WO2009127666A2 (en) * | 2008-04-15 | 2009-10-22 | Glaxosmithkline Biologicals S.A. | Method and compositions |
WO2010105815A2 (en) | 2009-03-17 | 2010-09-23 | Oncomethylome Sciences S.A. | Improved detection of gene expression |
JP2010532656A (en) * | 2007-01-15 | 2010-10-14 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Fusion protein containing cancer regression antigens NY-ESO-1 and LAGE-1 |
WO2010142685A1 (en) | 2009-06-10 | 2010-12-16 | Glaxosmithkline Biologicals S.A. | Adjuvant compositions comprising a non-ionic isotonicity agent |
WO2012095412A1 (en) * | 2011-01-10 | 2012-07-19 | Ct Atlantic Ltd. | Combination therapy including tumor associated antigen binding antibodies |
WO2013041572A1 (en) | 2011-09-20 | 2013-03-28 | Glaxosmithkline Biologicals S.A. | Liposome production using isopropanol |
US11179417B2 (en) | 2014-07-03 | 2021-11-23 | Transimmune Ag | Method for obtaining globally activated monocytes |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101381402B (en) * | 2008-10-20 | 2011-06-01 | 中国人民解放军第三军医大学 | NY-ESO-1 tumour antigen mimic epitope and use thereof |
RU2627447C2 (en) * | 2013-05-14 | 2017-08-08 | ЗОИТИС СЕРВИСЕЗ ЭлЭлСи | New vaccine compositions comprising immunostimulatory oligonucleotides |
ES2750608T3 (en) | 2013-07-25 | 2020-03-26 | Exicure Inc | Nucleic acid-based spherical constructs as immunostimulatory agents for prophylactic and therapeutic use |
EP3508198A1 (en) | 2014-06-04 | 2019-07-10 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
WO2016019298A2 (en) * | 2014-08-01 | 2016-02-04 | Texas Tech University System | Cancer testis antigen sperm protein 17 as a target for breast cancer immunotherapy and diagnosis |
AU2015349680A1 (en) | 2014-11-21 | 2017-06-08 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
US11945851B2 (en) | 2017-06-07 | 2024-04-02 | The Wistar Institute Of Anatomy And Biology | MAGE-A vaccines and methods of treatment using the same |
WO2019061297A1 (en) * | 2017-09-29 | 2019-04-04 | 苏州工业园区唯可达生物科技有限公司 | Cd4 helper t-cell epitope fusion peptide and vaccine thereof |
GB201804468D0 (en) * | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | PeptiCRAd Cancer Therapy |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999040188A2 (en) * | 1998-02-05 | 1999-08-12 | Smithkline Beecham Biologicals S.A. | Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccinations |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US5278302A (en) * | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
FR2649013B1 (en) * | 1989-07-03 | 1991-10-25 | Seppic Sa | VACCINES AND VECTORS OF FLUID ACTIVE INGREDIENTS CONTAINING METABOLIZABLE OIL |
FR2649012B1 (en) * | 1989-07-03 | 1991-10-25 | Seppic Sa | INJECTABLE MULTIPHASIC EMULSIONS |
US6055099A (en) * | 1996-02-23 | 2000-04-25 | British Telecommunications Public Limited Company | Optical interconnect |
US6686147B1 (en) * | 1998-07-15 | 2004-02-03 | Ludwig Institute For Cancer Research | Cancer associated antigens and uses therefor |
US20030044813A1 (en) * | 2001-03-30 | 2003-03-06 | Old Lloyd J. | Cancer-testis antigens |
-
2004
- 2004-05-04 GB GBGB0409940.4A patent/GB0409940D0/en not_active Ceased
-
2005
- 2005-05-02 RU RU2006138283/15A patent/RU2006138283A/en not_active Application Discontinuation
- 2005-05-02 AU AU2005237256A patent/AU2005237256A1/en not_active Abandoned
- 2005-05-02 BR BRPI0510570-6A patent/BRPI0510570A/en not_active IP Right Cessation
- 2005-05-02 JP JP2007512044A patent/JP2007536326A/en active Pending
- 2005-05-02 CN CNA2005800137978A patent/CN1980691A/en active Pending
- 2005-05-02 EP EP05741937A patent/EP1755657A2/en not_active Withdrawn
- 2005-05-02 WO PCT/EP2005/004956 patent/WO2005105139A2/en active Application Filing
- 2005-05-02 MX MXPA06012723A patent/MXPA06012723A/en not_active Application Discontinuation
- 2005-05-02 US US11/568,566 patent/US20070243196A1/en not_active Abandoned
- 2005-05-02 CA CA002564470A patent/CA2564470A1/en not_active Abandoned
- 2005-05-02 NZ NZ550967A patent/NZ550967A/en unknown
-
2006
- 2006-10-17 IL IL178681A patent/IL178681A0/en unknown
- 2006-10-18 ZA ZA200608693A patent/ZA200608693B/en unknown
- 2006-11-28 NO NO20065480A patent/NO20065480L/en not_active Application Discontinuation
- 2006-11-28 MA MA29494A patent/MA28639B1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999040188A2 (en) * | 1998-02-05 | 1999-08-12 | Smithkline Beecham Biologicals S.A. | Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccinations |
Non-Patent Citations (8)
Title |
---|
CHEN Y T ET AL: "A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 4 MAR 1997, vol. 94, no. 5, 4 March 1997 (1997-03-04), pages 1914-1918, XP002355506 ISSN: 0027-8424 * |
GAUGLER B ET AL: "HUMAN GENE MAGE-3 CODES FOR AN ANTIGEN RECOGNIZED ON A MELANOMA BY AUTOLOGOUS CYTOLYTIC T LYMPHOCYTES" JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 179, no. 3, 1 March 1994 (1994-03-01), pages 921-930, XP000576724 ISSN: 0022-1007 * |
JÄGER E ET AL: "Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 24 OCT 2000, vol. 97, no. 22, 24 October 2000 (2000-10-24), pages 12198-12203, XP002355504 ISSN: 0027-8424 * |
MASHINO K ET AL: "Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas." BRITISH JOURNAL OF CANCER. 1 SEP 2001, vol. 85, no. 5, 1 September 2001 (2001-09-01), pages 713-720, XP002355500 ISSN: 0007-0920 * |
REYNOLDS S R ET AL: "Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine." INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER. 17 SEP 1997, vol. 72, no. 6, 17 September 1997 (1997-09-17), pages 972-976, XP002355503 ISSN: 0020-7136 * |
REYNOLDS SANDRA R ET AL: "Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma." CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. FEB 2003, vol. 9, no. 2, February 2003 (2003-02), pages 657-662, XP002355502 ISSN: 1078-0432 * |
SUGITA YURIKA ET AL: "NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors." CANCER RESEARCH. 15 MAR 2004, vol. 64, no. 6, 15 March 2004 (2004-03-15), pages 2199-2204, XP002355501 ISSN: 0008-5472 * |
YAMAGUCHI HIROSHI ET AL: "Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response." CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 1 FEB 2004, vol. 10, no. 3, 1 February 2004 (2004-02-01), pages 890-896, XP002355505 ISSN: 1078-0432 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007137986A3 (en) * | 2006-05-26 | 2008-01-31 | Glaxosmithkline Biolog Sa | Vaccination against cancer |
WO2007137986A2 (en) * | 2006-05-26 | 2007-12-06 | Glaxosmithkline Biologicals Sa | Vaccination against cancer |
WO2007147876A3 (en) * | 2006-06-21 | 2008-05-15 | Glaxosmithkline Biolog Sa | Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage- a3 -marker |
US8936919B2 (en) | 2006-06-21 | 2015-01-20 | Glaxosmithkline Biologicals S.A. | Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the MAGE-A3-marker |
JP2009540812A (en) * | 2006-06-21 | 2009-11-26 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Method for detection and diagnosis of cancer comprising primers and probes for specific detection of MAGE-A3 marker |
AU2007263019B2 (en) * | 2006-06-21 | 2012-11-08 | Glaxosmithkline Biologicals S.A | Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the MAGE-A3-marker |
EA016347B1 (en) * | 2006-06-21 | 2012-04-30 | Глаксосмитклайн Байолоджикалс С.А. | Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage- a3 -marker |
JP2010532656A (en) * | 2007-01-15 | 2010-10-14 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Fusion protein containing cancer regression antigens NY-ESO-1 and LAGE-1 |
EP2457928A2 (en) | 2007-03-13 | 2012-05-30 | Universität Zürich | Monoclonal human tumor-specific antibody |
WO2008110372A1 (en) | 2007-03-13 | 2008-09-18 | University Of Zurich | Monoclonal human tumor-specific antibody |
US8519106B2 (en) | 2007-03-13 | 2013-08-27 | University Of Zurich | Monoclonal human tumor-specific antibody |
EP3159355A1 (en) | 2007-03-13 | 2017-04-26 | Universität Zürich | Monoclonal human tumor-specific antibody |
WO2008142133A1 (en) * | 2007-05-24 | 2008-11-27 | Glaxosmithkline Biologicals S.A | Lyophilised antigen composition |
US8557247B2 (en) | 2007-05-24 | 2013-10-15 | Glaxosmithkline Biologicals Sa | Lyophilised antigen composition |
WO2009127666A3 (en) * | 2008-04-15 | 2010-01-07 | Glaxosmithkline Biologicals S.A. | Vaccination compositions or combinations against cancer |
WO2009127666A2 (en) * | 2008-04-15 | 2009-10-22 | Glaxosmithkline Biologicals S.A. | Method and compositions |
WO2010105815A2 (en) | 2009-03-17 | 2010-09-23 | Oncomethylome Sciences S.A. | Improved detection of gene expression |
WO2010142685A1 (en) | 2009-06-10 | 2010-12-16 | Glaxosmithkline Biologicals S.A. | Adjuvant compositions comprising a non-ionic isotonicity agent |
WO2012095412A1 (en) * | 2011-01-10 | 2012-07-19 | Ct Atlantic Ltd. | Combination therapy including tumor associated antigen binding antibodies |
WO2013041572A1 (en) | 2011-09-20 | 2013-03-28 | Glaxosmithkline Biologicals S.A. | Liposome production using isopropanol |
US11179417B2 (en) | 2014-07-03 | 2021-11-23 | Transimmune Ag | Method for obtaining globally activated monocytes |
Also Published As
Publication number | Publication date |
---|---|
ZA200608693B (en) | 2010-01-27 |
NO20065480L (en) | 2006-11-28 |
MA28639B1 (en) | 2007-06-01 |
CN1980691A (en) | 2007-06-13 |
WO2005105139A3 (en) | 2006-04-13 |
BRPI0510570A (en) | 2007-11-20 |
AU2005237256A1 (en) | 2005-11-10 |
NZ550967A (en) | 2009-01-31 |
GB0409940D0 (en) | 2004-06-09 |
EP1755657A2 (en) | 2007-02-28 |
CA2564470A1 (en) | 2005-11-10 |
US20070243196A1 (en) | 2007-10-18 |
RU2006138283A (en) | 2008-06-10 |
MXPA06012723A (en) | 2007-02-14 |
IL178681A0 (en) | 2007-02-11 |
JP2007536326A (en) | 2007-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070243196A1 (en) | Mage-3 and NY-ESO-1 Based Polyvalent Vaccine for Cancer Immunotherapy | |
EP1889630B1 (en) | Vaccines comprising MAGE antigen linked to protein D fragment | |
JP4897547B2 (en) | vaccine | |
AU2002244337A1 (en) | Vaccines | |
JP2004511529A (en) | Adjuvant composition comprising immunostimulatory oligonucleotide and tocol | |
JP2008285487A (en) | Vaccines | |
PL203894B1 (en) | Vaccine composition and method for production thereof and the use | |
KR20070022064A (en) | Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy | |
ZA200302885B (en) | Vaccines. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 178681 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005237256 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2564470 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580013797.8 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 550967 Country of ref document: NZ Ref document number: 06110710 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11568566 Country of ref document: US Ref document number: 2007512044 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12006502167 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/012723 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005237256 Country of ref document: AU Date of ref document: 20050502 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005237256 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005741937 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3437/KOLNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200601980 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2005000604 Country of ref document: DZ Ref document number: DZP2006000604 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067025554 Country of ref document: KR Ref document number: 2006138283 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067025554 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005741937 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11568566 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0510570 Country of ref document: BR |